检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:向惠[1] 衡明强 XIANG Hui;HENG Mingqiang(Department of Rheumatology,The People's Hospital of Changji Hui Autonomous Prefecture,Changji Yinjiang 831100,China;Internal Medicine-Cardiovascular Department)
机构地区:[1]新疆昌吉回族自治州人民医院风湿免疫科,新疆昌吉831100 [2]新疆昌吉回族自治州人民医院心血管内科,新疆昌吉831100
出 处:《中国继续医学教育》2018年第19期127-128,共2页China Continuing Medical Education
摘 要:目的分析沙利度胺与注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白(益赛普)联合使用对难治性强直性脊柱炎的治疗效果,以及其对患者ESR、CRP水平的影响。方法给予对照组中患者皮下注射注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白。给予研究组中患者行沙利度胺与注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白的联合疗法,观察两组临床指标及治疗效果。结果研究组治疗后,患者的晨僵时间、关节的疼痛个数、枕壁距、胸廓的扩张度和BASFI、CRP、ESR与对照组相比,差异有统计学意义(P<0.05)。研究组总有效率高于对照组(P<0.05)。结论沙利度胺与注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白的联合使用对难治性的强直性的脊柱炎有较好的疗效,能显著改善患者临床症状。Objective To analyze the effect of treatment with thalidomide and recombinant human tumor necrosis factor receptor antibody fusion protein for injection for refractory ankylosing spondylitis, and its effect on patients with ESR and CRP levels. Methods Patients in control group were given recombinant human tumor necrosis factor receptor antibody fusion protein for injection. Patients in the study group were treated with thalidomide combined with recombinant human tumor necrosis factor receptor antibody fusion protein for injection. The clinical indicators and treatment effect in two groups were observed. Results In study group, the morning stiffness time, joint pain, occipital wall distance, chest expansion and BASFI, CRP and ESR were compared with those of the control group, the difference was statistically significant(P〈 0.05). The total effective rate of the study group was higher than that of the control group(P〈 0.05). Conclusion There is a good effect with thalidomide and recombinant human tumor necrosis factor receptor antibody fusion protein for injection in ankylosing spondylitis of refractory, can significantly improve the clinical symptoms.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.3